

Registered Biosimilar Medicines in Belgium

Update of March 2022

Molecule	Biosimilar product	Date of reimbursement
Adalimumab	Amgevita	March 2017
	Imraldi	August 2017
	Hyrimoz	July 2018
	Hulio	September 2018
	Idacio	April 2019
	Yuflyma	September 2021
Bevacizumab	Mvasi	September 2020
	Zirabev	October 2020
	Oyavas	August 2021
Enoxaparin sodium	Ghemaxan	January 2021
Epoetin alpha	Binocrit	September 2008
Etanercept	Benepali	January 2016
	Erelzi	July 2019
	Nepexto	February 2021
Filgrastim	Accofil	June 2016
	Nivestim	March 2014
	Tevagrastim	February 2010
Follitropin alpha	Bemfola	N/A
	Ovaleap	N/A
Infliximab	Remsima	April 2015 (SC since March 2021)
	Flixabi	May 2017
	Inflectra	April 2015
	Zessly	January 2019
Insulin glargine	Abasaglar	June 2016
Pegfilgrastim	Pelgraz	April 2019
	Ziextenzo	July 2019
	Pelmeg	May 2019
Rituximab	Truxima	November 2017
	Ruxience	January 2022
	Rixathon	October 2018
Somatropin	Omnitrope	April 2014
Trastuzumab	Kanjinti	January 2019
	Ogivri	July 2019
	Herzuma	August 2018
	Ontruzant	May 2019
	Trazimera	June 2019
	Zercepac	June 2021